Company research
Endo LP
CIK 2008861Updated Sep 26, 2026
Name history
Endo, Inc. · through Jun 25, 2025
Filing activity
Latest filing
50 filings on record · 15-15D, EFFECT, S-8 POS, POS AM, 8-K, DEFA14A.
About the company
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Recent filings
15-15D filing
EFFECT filing
S-8 POS filing
POS AM filing
Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 |
|---|---|
| ASSETS | |
| AssetsUSD | 5,087,398,000Source |
| GoodwillUSD | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,225,491,000Source |
| Current assets: | |
| Cash and Cash Equivalents, at Carrying ValueUSD | 220,607,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 400,519,000Source |
| Inventory, NetUSD | 873,073,000Source |
| Assets, CurrentUSD | 1,755,847,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 85,128,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,373,000Source |
| Other Assets, NoncurrentUSD | 498,237,000Source |
| LIABILITIES AND EQUITY | |
| Stockholders’ equity: | |
| Common Stock, Value, IssuedUSD | 76,000Source |
| Additional Paid in CapitalUSD | 1,981,480,000Source |
| Retained Earnings (Accumulated Deficit)USD | 0Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 1,981,556,000Source |
| Liabilities and EquityUSD | 5,087,398,000Source |
| Current liabilities: | |
| Liabilities, CurrentUSD | 518,227,000Source |
| Operating Lease, Liability, CurrentUSD | 4,256,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,914,000Source |
| Deferred Income Tax Liabilities, NetUSD | 69,010,000Source |
| Other Liabilities, NoncurrentUSD | 67,036,000Source |
| Additional Financial Items | |
| Long-term Debt, Current MaturitiesUSD | 7,500,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,429,031,000Source |
cash flow · annual statements
| Line item | FY 2024 |
|---|---|
| Cash flows from operating activities: | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| Depreciation and amortization | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,286,000Source |
| Changes in operating assets and liabilities: | |
| Increase (Decrease) in Accounts ReceivableUSD | 17,022,000Source |
| Increase (Decrease) in InventoriesUSD | 5,530,000Source |
| Deferred Income Tax Expense (Benefit)USD | -232,783,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 113,419,000Source |
| Cash flows from investing activities: | |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -20,874,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 36,993,000Source |
| Cash flows from financing activities: | |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -12,920,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 79,425,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 476,430,000Source |
| Supplemental disclosure of cash flow information: | |
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 141,875,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -200,000Source |
| Additional Financial Items | |
| Share-based Payment Arrangement, ExpenseUSD | 3,286,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 5,623,000Source |
| Amortization of Intangible AssetsUSD | 173,600,000Source |
| DepreciationUSD | 46,200,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,614,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 6,630,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | -203,000Source |
| GoodwillUSD | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -730,864,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | -163,000Source |
| Income Tax Expense (Benefit)USD | -131,023,000Source |
| Net Income (Loss) Attributable to ParentUSD | -730,864,000Source |
| Nonoperating Income (Expense)USD | 9,769,000Source |
| Other Nonoperating Income (Expense)USD | 688,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source |
| Proceeds from Stock Options ExercisedUSD | 0Source |
income statement · annual statements
| Line item | FY 2024 |
|---|---|
| Total RevenueUSD | 1,178,166,000Source |
| Cost of Goods and Services Sold | — |
| Gross Profit (Calculated) · Derived | — |
| Selling, General and Administrative ExpenseUSD | 382,629,000Source |
| Other Nonoperating Income (Expense)USD | 688,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -861,887,000Source |
| Income Tax Expense (Benefit)USD | -131,023,000Source |
| Net Income (Loss) Attributable to ParentUSD | -730,864,000Source |
| Earnings Per Share, BasicUSD per share | -9.6Source |
| Earnings Per Share, DilutedUSD per share | -9.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 76,156,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 76,156,000Source |
| Additional Financial Items | |
| Amortization of Intangible AssetsUSD | 173,600,000Source |
| Business Combination, Acquisition Related CostsUSD | 2,370,000Source |
| Current Income Tax Expense (Benefit)USD | 101,760,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 219,758,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,614,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | -203,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -730,864,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -35,127,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -9.6Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -9.6Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | -163,000Source |
| Interest Income (Expense), NetUSD | -164,051,000Source |
| Nonoperating Income (Expense)USD | 9,769,000Source |
Filing attachments
d926314dex991.htm · 8-K · 2025-03-13
EX-99.1 2 d926314dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results Endo achieved 2024 revenues and adjusted EBITDA expectations, while progressing the Company’s strategic priorities XIAFLEX® hit record revenues of $516 million in 2024, up 9% versus 2023 The Company provides 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million MALVERN, Pa., March 13, 2025 - Endo, Inc. (“E…
Read attachment ↗d926314dex992.htm · 8-K · 2025-03-13
EX-99.2 3 d926314dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader Transaction Brings Together Two Highly Complementary Businesses to Broaden Patient Access and Develop New Therapies to Address Unmet Patient Needs Combined Company Expected to Benefit from Immediate Scale, Robust Cash Flow and Enhanced Financial Flexibility to Invest in Internal and External Growth Opportunities; Net Leverage of Appro…
Read attachment ↗